Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87641295 | 8764129 | 5 | F | 20160715 | 20120831 | 20160726 | EXP | US-ASTRAZENECA-2011SE51516 | ASTRAZENECA | 71.00 | YR | F | Y | 72.60000 | KG | 20160726 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87641295 | 8764129 | 1 | PS | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 80 MCG, TWO TIMES A DAY | 21929 | BID | |||||||||
| 87641295 | 8764129 | 2 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 87641295 | 8764129 | 3 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 87641295 | 8764129 | 4 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | 40 | MG | CAPSULE | BID | |||||||
| 87641295 | 8764129 | 5 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | 40 | MG | CAPSULE | BID | |||||||
| 87641295 | 8764129 | 6 | SS | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | 0 | CAPSULE | |||||||||
| 87641295 | 8764129 | 7 | SS | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | N | U | 0 | |||||||||
| 87641295 | 8764129 | 8 | SS | PRILOSEC OTC | OMEPRAZOLE MAGNESIUM | 1 | Oral | N | U | 0 | MODIFIED-RELEASE TABLET | ||||||||
| 87641295 | 8764129 | 9 | SS | ALBUTEROL. | ALBUTEROL | 1 | Unknown | U | 0 | ||||||||||
| 87641295 | 8764129 | 10 | C | MAGNESIUM | MAGNESIUM | 1 | Oral | 0 | 400 | MG | BID | ||||||||
| 87641295 | 8764129 | 11 | C | AMBIEN | ZOLPIDEM TARTRATE | 1 | Oral | 0 | 10 | MG | QD | ||||||||
| 87641295 | 8764129 | 12 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Respiratory (inhalation) | 0 | 18 | UG | QD | ||||||||
| 87641295 | 8764129 | 13 | C | NORVASC | AMLODIPINE BESYLATE | 1 | Oral | 0 | 5 | MG | QD | ||||||||
| 87641295 | 8764129 | 14 | C | NORVASC | AMLODIPINE BESYLATE | 1 | Oral | 0 | 5 | MG | BID | ||||||||
| 87641295 | 8764129 | 15 | C | XANAX | ALPRAZOLAM | 1 | Oral | 0 | 1 | MG | QD | ||||||||
| 87641295 | 8764129 | 16 | C | ALPRAZOLAM. | ALPRAZOLAM | 1 | 0 | 1 | MG | QD | |||||||||
| 87641295 | 8764129 | 17 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | 0 | 88 | MG | QD | |||||||||
| 87641295 | 8764129 | 18 | C | LOSARTAN. | LOSARTAN | 1 | 0 | 50 | MG | QD | |||||||||
| 87641295 | 8764129 | 19 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 0 | 1.5 | DF | TABLET | QD | ||||||||
| 87641295 | 8764129 | 20 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | 0 | 5 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 87641295 | 8764129 | 1 | Chronic obstructive pulmonary disease |
| 87641295 | 8764129 | 2 | Ulcer |
| 87641295 | 8764129 | 3 | Gastrooesophageal reflux disease |
| 87641295 | 8764129 | 4 | Ulcer |
| 87641295 | 8764129 | 5 | Gastrooesophageal reflux disease |
| 87641295 | 8764129 | 7 | Gastrooesophageal reflux disease |
| 87641295 | 8764129 | 8 | Gastrooesophageal reflux disease |
| 87641295 | 8764129 | 10 | Epigastric discomfort |
| 87641295 | 8764129 | 11 | Insomnia |
| 87641295 | 8764129 | 12 | Chronic obstructive pulmonary disease |
| 87641295 | 8764129 | 13 | Hypertension |
| 87641295 | 8764129 | 14 | Hypertension |
| 87641295 | 8764129 | 15 | Sleep disorder therapy |
| 87641295 | 8764129 | 16 | Sleep disorder |
| 87641295 | 8764129 | 17 | Goitre |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 87641295 | 8764129 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 87641295 | 8764129 | Body height decreased | |
| 87641295 | 8764129 | Cataract | |
| 87641295 | 8764129 | Chest pain | |
| 87641295 | 8764129 | Chronic obstructive pulmonary disease | |
| 87641295 | 8764129 | Drug dose omission | |
| 87641295 | 8764129 | Drug hypersensitivity | |
| 87641295 | 8764129 | Drug ineffective | |
| 87641295 | 8764129 | Dyspepsia | |
| 87641295 | 8764129 | Epistaxis | |
| 87641295 | 8764129 | Eructation | |
| 87641295 | 8764129 | Gastrooesophageal reflux disease | |
| 87641295 | 8764129 | Goitre | |
| 87641295 | 8764129 | Intentional product use issue | |
| 87641295 | 8764129 | Mental disorder | |
| 87641295 | 8764129 | Myocardial infarction | |
| 87641295 | 8764129 | Off label use | |
| 87641295 | 8764129 | Regurgitation | |
| 87641295 | 8764129 | Thyroid pain | |
| 87641295 | 8764129 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 87641295 | 8764129 | 1 | 201106 | 0 | ||
| 87641295 | 8764129 | 2 | 1990 | 0 | ||
| 87641295 | 8764129 | 3 | 1990 | 0 | ||
| 87641295 | 8764129 | 4 | 20160615 | 0 | ||
| 87641295 | 8764129 | 5 | 20160615 | 0 | ||
| 87641295 | 8764129 | 10 | 201109 | 0 | ||
| 87641295 | 8764129 | 11 | 1990 | 0 |